Adjuvant donafenib plus anti–PD-1 therapy in hepatocellular carcinoma with high-risk features after curative resection: A real-world study.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2026-05-28
DOI
https://doi.org/10.1200/jco.2026.44.16_suppl.e16254
Primary Topic
Hepatocellular Carcinoma Treatment and Prognosis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Adjuvant donafenib plus anti–PD-1 therapy in hepatocellular carcinoma with high-risk features after curative resection: A real-world study.

Hanchuan Shen, Yang Liu, Chenggang Li, Chaoxian Li et al.
Journal of Clinical Oncology
Hepatocellular Carcinoma Treatment and Prognosis
article

Adjuvant donafenib plus anti–PD-1 therapy in hepatocellular carcinoma with high-risk features after curative resection: A real-world study.

Hanchuan Shen, Yang Liu, Chenggang Li, Chaoxian Li, Tianci Zhao
article en

Abstract

No abstract available for this paper.
Journal of Clinical OncologyVol. 44(16_suppl)
Chinese PLA General Hospital (CN)
Good health and well-being
Openalex Percentile: Top 7%
Hepatocellular Carcinoma Treatment and Prognosis
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.